.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Moodys
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Queensland Health
Medtronic
McKesson
Express Scripts
Baxter

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,780,881

« Back to Dashboard

Which drugs does patent 6,780,881 protect, and when does it expire?


Patent 6,780,881 protects PROTONIX IV and is included in one NDA.

Protection for PROTONIX IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in forty countries.

Summary for Patent: 6,780,881

Title: Freeze-dried pantoprazole preparation and pantoprazole injection
Abstract:Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
Inventor(s): Linder; Rudolf (Constance, DE), Dietrich; Rango (Constance, DE)
Assignee: Altana Pharma AG (Constance, DE)
Application Number:10/195,062
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Wyeth Pharms IncPROTONIX IVpantoprazole sodiumINJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,780,881

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
00125569Nov 22, 2000

Non-Orange Book Patents for Patent: 6,780,881

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,723Freeze-dried pantoprazole preparation and pantoprazole injection► Subscribe
8,754,108Freeze-dried pantoprazole preparation and pantoprazole injection► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,780,881

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Yugoslavia37703► Subscribe
Portugal1339430► Subscribe
Poland201188► Subscribe
Poland361118► Subscribe
Peru05822002► Subscribe
New Zealand525911► Subscribe
Norway332937► Subscribe
Norway20032303► Subscribe
Malaysia137726► Subscribe
MexicoPA03004548► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Mallinckrodt
Fuji
Fish and Richardson
Cerilliant
Deloitte
Julphar
Baxter
UBS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot